Janus Henderson Group PLC lessened its stake in Teleflex Incorporated (NYSE:TFX - Free Report) by 2.2% during the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 5,259,056 shares of the medical technology company's stock after selling 117,396 shares during the quarter. Janus Henderson Group PLC owned approximately 11.32% of Teleflex worth $936,007,000 at the end of the most recent reporting period.
A number of other large investors also recently modified their holdings of TFX. Vontobel Holding Ltd. boosted its position in Teleflex by 21.9% in the fourth quarter. Vontobel Holding Ltd. now owns 1,393 shares of the medical technology company's stock worth $248,000 after purchasing an additional 250 shares during the last quarter. Sumitomo Mitsui Trust Group Inc. raised its stake in shares of Teleflex by 5.2% in the fourth quarter. Sumitomo Mitsui Trust Group Inc. now owns 108,231 shares of the medical technology company's stock valued at $19,263,000 after buying an additional 5,322 shares during the period. Lecap Asset Management Ltd. bought a new stake in shares of Teleflex in the fourth quarter valued at $729,000. Mirae Asset Global Investments Co. Ltd. raised its stake in shares of Teleflex by 35.1% in the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 5,875 shares of the medical technology company's stock valued at $1,053,000 after buying an additional 1,527 shares during the period. Finally, Boston Trust Walden Corp raised its stake in shares of Teleflex by 3.9% in the fourth quarter. Boston Trust Walden Corp now owns 294,614 shares of the medical technology company's stock valued at $52,435,000 after buying an additional 11,052 shares during the period. Institutional investors own 95.62% of the company's stock.
Teleflex Stock Up 2.1%
TFX stock traded up $2.66 on Friday, reaching $129.15. 506,437 shares of the company traded hands, compared to its average volume of 640,107. Teleflex Incorporated has a one year low of $120.06 and a one year high of $249.91. The company has a debt-to-equity ratio of 0.37, a current ratio of 2.42 and a quick ratio of 1.39. The company has a market cap of $5.71 billion, a P/E ratio of 25.67, a price-to-earnings-growth ratio of 1.73 and a beta of 1.17. The firm has a fifty day simple moving average of $133.03 and a 200-day simple moving average of $163.88.
Teleflex (NYSE:TFX - Get Free Report) last posted its earnings results on Thursday, May 1st. The medical technology company reported $2.91 EPS for the quarter, topping analysts' consensus estimates of $2.88 by $0.03. The business had revenue of $700.67 million during the quarter, compared to analyst estimates of $699.37 million. Teleflex had a return on equity of 14.19% and a net margin of 7.85%. The company's quarterly revenue was down 5.0% compared to the same quarter last year. During the same quarter last year, the company earned $3.21 EPS. Research analysts anticipate that Teleflex Incorporated will post 13.98 earnings per share for the current year.
Teleflex Dividend Announcement
The firm also recently declared a quarterly dividend, which will be paid on Monday, June 16th. Shareholders of record on Tuesday, May 20th will be issued a dividend of $0.34 per share. The ex-dividend date is Tuesday, May 20th. This represents a $1.36 dividend on an annualized basis and a yield of 1.05%. Teleflex's dividend payout ratio is presently 42.90%.
Analyst Ratings Changes
Several analysts have issued reports on the company. Raymond James lowered Teleflex from an "outperform" rating to a "market perform" rating in a research note on Friday, February 28th. Mizuho set a $155.00 price objective on Teleflex in a research note on Wednesday, April 16th. Truist Financial decreased their price objective on Teleflex from $140.00 to $137.00 and set a "hold" rating on the stock in a research note on Monday, May 5th. StockNews.com lowered Teleflex from a "buy" rating to a "hold" rating in a research note on Friday, February 28th. Finally, Bank of America lowered Teleflex from a "neutral" rating to an "underperform" rating and decreased their price objective for the company from $235.00 to $140.00 in a research note on Tuesday, March 4th. One analyst has rated the stock with a sell rating, nine have assigned a hold rating and two have given a buy rating to the stock. Based on data from MarketBeat, Teleflex has an average rating of "Hold" and a consensus price target of $164.63.
Get Our Latest Report on Teleflex
Teleflex Profile
(
Free Report)
Teleflex Incorporated designs, develops, manufactures, and supplies single-use medical devices for common diagnostic and therapeutic procedures in critical care and surgical applications worldwide. The company provides vascular access products that comprise Arrow branded catheters, catheter navigation and tip positioning systems, and intraosseous access systems for the administration of intravenous therapies, the measurement of blood pressure, and the withdrawal of blood samples through a single puncture site.
See Also
Before you consider Teleflex, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Teleflex wasn't on the list.
While Teleflex currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
